Ken F. Blount, Ph.D
Dr. Ken Blount is a seasoned director of research in biotech, pharma, clinical, and academic research settings, and his scientific expertise includes antibiotics discovery and development, fecal microbiome analysis, translational medical oncology, and RNA-targeting therapeutics. Prior to joining Rebiotix, Dr. Blount coordinated translational urologic oncology research for the Yale Cancer Center. He was a cofounder and Director of Biology at BioRelix, a biotech that developed new antibiotics to target structured bacterial messenger RNAs. At BioRelix, he led a force of internal scientists and external resources that delivered development candidates for treating Clostridium difficile infections.
Dr. Blount received his BS in biochemistry from the University of Arkansas, a PhD in biochemistry from the University of Colorado Boulder, after which he completed an NIH post-doctoral fellowship at the University of California San Diego.